Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor α function in breast cancer via the Wnt pathway.

Lim SK, Orhant-Prioux M, Toy W, Tan KY, Lim YP.

FASEB J. 2011 Sep;25(9):3004-18. doi: 10.1096/fj.10-169136. Epub 2011 Jun 3.

PMID:
21642474
[PubMed - indexed for MEDLINE]
Free Article
2.

c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation.

He X, Zheng Z, Song T, Wei C, Ma H, Ma Q, Zhang Y, Xu Y, Shi W, Ye Q, Zhong H.

Oncogene. 2010 Apr 15;29(15):2238-51. doi: 10.1038/onc.2009.513. Epub 2010 Jan 25.

PMID:
20101225
[PubMed - indexed for MEDLINE]
3.

Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.

Ford CE, Ekström EJ, Andersson T.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24. doi: 10.1073/pnas.0809516106. Epub 2009 Feb 23. Retraction in: Ford CE, Ekström EJ, Anderson T. Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22360.

PMID:
19237581
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.

Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA.

Mol Cancer Ther. 2006 Dec;5(12):3023-31.

PMID:
17172405
[PubMed - indexed for MEDLINE]
Free Article
5.

A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA.

Breast Cancer Res Treat. 2010 Jul;122(2):381-93. doi: 10.1007/s10549-009-0580-1. Epub 2009 Oct 20.

PMID:
19842032
[PubMed - indexed for MEDLINE]
6.

Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.

Deol YS, Nasser MW, Yu L, Zou X, Ganju RK.

J Biol Chem. 2011 Dec 30;286(52):44845-54. doi: 10.1074/jbc.M111.225466. Epub 2011 Oct 20.

PMID:
22016394
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src.

Liu H, Qiu J, Li N, Chen T, Cao X.

J Biol Chem. 2010 Jul 16;285(29):21934-42. doi: 10.1074/jbc.M110.109876. Epub 2010 May 11.

PMID:
20460377
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system.

Silberstein GB, Van Horn K, Hrabeta-Robinson E, Compton J.

J Endocrinol. 2006 Aug;190(2):225-39.

PMID:
16899557
[PubMed - indexed for MEDLINE]
Free Article
9.

Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.

Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE.

Mol Cancer Res. 2007 Jan;5(1):71-85.

PMID:
17259347
[PubMed - indexed for MEDLINE]
Free Article
10.

Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells.

Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, de Falco A, Barone MV, Abbondanza C, Migliaccio A, Auricchio F.

Oncogene. 2012 Nov 15;31(46):4868-77. doi: 10.1038/onc.2011.642. Epub 2012 Jan 23.

PMID:
22266855
[PubMed - indexed for MEDLINE]
11.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
[PubMed - indexed for MEDLINE]
12.

Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.

Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B.

J Endocrinol. 2005 Jun;185(3):577-92.

PMID:
15930183
[PubMed - indexed for MEDLINE]
Free Article
13.

Tamoxifen induces the expression of maspin through estrogen receptor-alpha.

Liu Z, Shi HY, Nawaz Z, Zhang M.

Cancer Lett. 2004 Jun 8;209(1):55-65.

PMID:
15145521
[PubMed - indexed for MEDLINE]
14.

The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.

Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE.

Mol Cancer. 2010 Jun 15;9:150. doi: 10.1186/1476-4598-9-150.

PMID:
20550710
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.

Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M.

Cancer Res. 2007 Feb 15;67(4):1859-66.

PMID:
17308128
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-alpha-positive breast cancer cells.

Li Q, Wu L, Oelschlager DK, Wan M, Stockard CR, Grizzle WE, Wang N, Chen H, Sun Y, Cao X.

J Biol Chem. 2005 Jul 22;280(29):27022-8. Epub 2005 May 10.

PMID:
15886208
[PubMed - indexed for MEDLINE]
Free Article
18.

Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.

Foldynová-Trantírková S, Sekyrová P, Tmejová K, Brumovská E, Bernatík O, Blankenfeldt W, Krejcí P, Kozubík A, Dolezal T, Trantírek L, Bryja V.

Breast Cancer Res. 2010;12(3):R30. doi: 10.1186/bcr2581. Epub 2010 May 27.

PMID:
20507565
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.

Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA.

Eur J Cancer. 2010 Jun;46(9):1679-91. doi: 10.1016/j.ejca.2010.02.036. Epub 2010 Mar 29.

PMID:
20350802
[PubMed - indexed for MEDLINE]
20.

Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.

Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chaiwun B, Lin F, Imam SA, Marsh JL, Holcombe RF.

Int J Oncol. 2005 Oct;27(4):949-56.

PMID:
16142310
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk